Free Trial
LON:VAL

ValiRx (VAL) Share Price, News & Analysis

→ Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad)
Free VAL Stock Alerts
GBX 3.40
-0.05 (-1.57%)
(As of 04:22 AM ET)
Compare
Today's Range
3.40
▼
3.47
50-Day Range
3.42
▼
4.90
52-Week Range
3.30
▼
15
Volume
73,034 shs
Average Volume
757,677 shs
Market Capitalization
£4.49 million
P/E Ratio
N/A
Dividend Yield
0.63%
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlines
VAL stock logo

About ValiRx Stock (LON:VAL)

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.

VAL Stock Price History

VAL Stock News Headlines

February 28, 2024 | msn.com
New method discovered to halt active cancer cells
February 27, 2024 | uk.news.yahoo.com
Scientists discover 'two-punch' method to eliminate cancer cells
April 25, 2024 | Paradigm Press (Ad)
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
February 13, 2024 | lse.co.uk
ValiRx says requisition notice from shareholder group is invalid
February 9, 2024 | lse.co.uk
TRADING UPDATES: ValiRx receives shareholder request for board change
December 5, 2023 | markets.businessinsider.com
European Stocks Close Mostly Higher
December 5, 2023 | markets.businessinsider.com
European Markets Move Mostly Higher
December 5, 2023 | lse.co.uk
ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose
April 25, 2024 | Banyan Hill Publishing (Ad)
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
November 15, 2023 | morningstar.com
ValiRx PLC EAJF
November 10, 2023 | lse.co.uk
ValiRx signs deal to evaluate StingRay Bio drug candidates
October 6, 2023 | lse.co.uk
CORRECT (Oct 5): ICG Enterprise ups interim payout on better results
October 6, 2023 | lse.co.uk
ValiRx sees no reason for shares jump; notes TheoremRx mulls merger
September 11, 2023 | finance.yahoo.com
VAL.L - ValiRx plc
August 24, 2023 | lse.co.uk
ValiRx interim loss widens as costs increase; hails Inaphaea progress
August 24, 2023 | marketwatch.com
ValiRx Shares Rise on Higher Income Expectations From Inaphaea BioLabs
August 14, 2023 | lse.co.uk
ValiRx signs collaborative services agreement with Agility
August 14, 2023 | marketwatch.com
ValiRx Shares Rise After Collaborative Services Agreement With Agility
July 19, 2023 | marketwatch.com
ValiRx Shares Rise After Subsidiary Secures Contract
June 28, 2023 | lse.co.uk
TRADING UPDATES: All Things Considered raises funds to buy Sandbag
June 16, 2023 | lse.co.uk
ValiRx shares drop after cancer drug research dropped
June 16, 2023 | marketwatch.com
ValiRx Shares Fall After Cancer-Drug Development Abandoned
June 8, 2023 | marketwatch.com
ValiRx Changes IP Exclusivity Terms With TheoremRx to Exclude Greater China
June 7, 2023 | lse.co.uk
ValiRx expands cancer research agreement with University of Barcelona
June 3, 2023 | lse.co.uk
Self Storage Gr Share Chat
May 4, 2023 | msn.com
Milner Therapeutics Institute welcomes Cathy Tralau-Stewart as executive director
March 26, 2023 | marketwatch.com
Global Endometriosis Drugs Market Research Growth, Regions, Type and Application, Forecast Analysis to 2023-2030 By VMReports
See More Headlines
Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/07/2020
Today
4/24/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:VAL
CUSIP
N/A
CIK
N/A
Web
www.valirx.com
Phone
+44-20-30084416
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-2,410,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.39%
Return on Assets
-47.22%

Debt

Debt-to-Equity Ratio
0.73
Current Ratio
13.37
Quick Ratio
1.27

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
GBX 0.06 per share
Price / Cash Flow
62.50
Book Value
GBX 4 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
132,350,000
Free Float
N/A
Market Cap
£4.57 million
Optionable
Not Optionable
Beta
0.63
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Suzanne J. Dilly B.Sc. (Age 46)
    BSc, Ph.D., CEO & Director
    Comp: $160.85k
  • Mr. James Gerry Desler FCA (Age 79)
    CFO, Company Secretary & Executive Director
    Comp: $53k
  • Mr. Kumar Nawani
    Head of Operations
  • Dr. Catherine Jane Tralau-Stewart Ph.D.
    Chief Scientific Officer & Board Observer
  • Mr. Tarquin Edwards
    Head of Investor Relations & Communications
  • Mr. Mark Treharne
    Corporate Development Manager

Key Competitors

View All Competitors

VAL Stock Analysis - Frequently Asked Questions

How have VAL shares performed in 2024?

ValiRx's stock was trading at GBX 5.90 at the beginning of 2024. Since then, VAL stock has decreased by 42.4% and is now trading at GBX 3.40.
View the best growth stocks for 2024 here.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) released its earnings results on Monday, September, 7th. The company reported ($4.43) EPS for the quarter.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:VAL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
Bitcoin Rockets To Record High But Buy THIS Instead
Paradigm Press
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Fed launches fourth dollar overhaul
Stansberry Research
1970’s computer coder issues shocking A.I. warning
TradeSmith
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders
New Trump Bombshell
The Freeport Society
Man Who Predicted 2008: “This Will be Worse.”
Altimetry